Satellite Forums 2019


The forums and workshops are designed to offer a more intimate environment to tackle the key issues head on.

11:00


LSX Pharma BD Forum 200xhostsGoldman SachsFreshfields Bruckhaus Deringer

Pharma BD Forum is a high profile forum designed primarily for global and regional BD heads from the larger and mid cap ( >$1bn) Pharma and Biotech companies, and key influential partners and stakeholders in the sector.

The forum will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole. This is an invite-only forum and not open to general attendees.


LSX 1-2-1 Partnering 200x                 hosted by Longevity Leaders

1-2-1 partnering will take place in a dedicated room with private meeting tables and 30min allocated slots.

8 hours of enabled partnering outside of the informal networking during breaks will be scheduled from approx. 9am - 5pm.

 


LSX Clinical Workshop 200x              hosted by   IQVIA

The clinical strategies workshop is a 1.5hr intimate, interactive forum in which a leading CRO partner hosts an intimate group of CxOs who are transitioning into clinical development and interested in exploring business models and approaches to partnerships in clinical trials.

This workshop can be added as a free-to-attend agenda item. Limited places available.

Panel: Clinical Strategies Workshop: Capturing the attention of investors
Michael Kardas, Vice President, Strategic Drug Development, IQVIA
Patrick Jordan, CEO, Mycovia
Thomas Goodin, Senior Director, Clinical Development, Sunovion Pharmaceuticals Inc.

This is a unique opportunity for candid sharing of experiences with an intimate group of biopharma executives transitioning into clinical development. The session includes:

  • Discussion of the key elements of long term strategic planning that enables you to articulate a compelling value to investors.
  • Panel discussion with biopharma executives
  • Q&A session

 


 Licensing and collaboration workshop-1      hosted by    Wilson Sonsini

The licensing and collaboration workshop is a 1.5hr intimate, interactive forum in which CEOs and CBOs navigate the how, what, where and when of a successful licensing deal / strategic collaboration.

Delivering strategy, tactics, mechanics and idea the workshop can be added as a free-to-attend agenda item. Limited places available.

Licensing & Collaboration Deals: Trends and Drivers
Farah Gerdes, Partner, Technology Transactions, Wilson Sonsini Goodrich & Rosati

  • Why collaborate?
  • Market Trends & Drivers
  • Traditional drivers
  • Early stage vs. Late Stage
  • Deal elements that drive value
  • Beyond the NCE – subject matter/technology being licensed
  • The changing the face of collaborations:
  • Technology
  • Big Data
  • Open innovation

Case study of a successful licensing deal
Shakti Narayan,
CEO, Accent Therapeutics

Key Considerations in Licensing & Collaboration Deals

The Collaboration Lifecycle, Key terms, Scope, Governance, Financials, IP, Exit, Impact of trends on deal terms and Future-proofing the deal

12:50


Networking Lunch

13:50


LSX Pharma BD Forum 200x hostsGoldman SachsFreshfields Bruckhaus Deringer

Pharma BD Forum is a high profile forum designed primarily for global and regional BD heads from the larger and mid cap ( >$1bn) Pharma and Biotech companies, and key influential partners and stakeholders in the sector.

The forum will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole. This is an invite-only forum and not open to general attendees.


LSX 1-2-1 Partnering 200x                hosted by  Longevity Leaders

1-2-1 partnering will take place in a dedicated room with private meeting tables and 30min allocated slots.

8 hours of enabled partnering outside of the informal networking during breaks will be scheduled from approx. 9am - 5pm.


Value Pricing 200x          hosted by  Arnold Porter

The value-based pricing and contracting workshop is a 1.5hr intimate, interactive forum for CEOs who are implementing value-based strategies in order to meet the needs of the patients, payers and regulators.

Workshop leaders

Jeffrey Handwerker, Partner, Arnold & Porter
Ariane Horn, Partner, Arnold & Porter

The workshop can be added as a free-to-attend agenda item. Limited places available.

13.50 Overview of Value-Based Strategies

  • What is a Value-Based Arrangement?
  • Why Value-Based Arrangements Are of Interest to Manufacturers, Payers, State
  • Agencies and other Stakeholders?
  • Types of Agreements
  • Key Legal Considerations
    • Anti-Kickback Statute
    • Drug Price Reporting
    • Off-Label Promotion
    • Privacy
    • Government Transparency

14.30 Business Perspectives on Value-Based Strategies

  • Jeff Berkowitz, CEO and Director, Real Endpoints

14.50 Case Studies / Panel Discussion

  • Payer rebates based on adherence measures
  • Payer rebates based on failure to achieve pre-specified efficacy measures
  • Payer rebates based on total costs of care for patients on one drug versus patients on different drugs
  • Hospital delayed payment pending achievement of pre-specified efficacy measures

15:30


Networking Break

DOWNLOAD THE BROCHURE